This two-part issue, edited by Dr. Rathan Subramaniam, reviews current clinical information in "PET/CT and Patient Outcomes." In Part II of this issue, articles will include: Hepatobiliary and Pancreatic Cancer; Endometrial, Cervical & Ovarian Cancer; Renal, Bladder and Testicular Cancer; Musculoskeletal and Soft Tissue Tumors; Myocardial Perfusion / Viability; Unknown Primary Cancer; Gastric Cancer; Brain Tumors; Neuroendocrine Tumors, and more!
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 8 7. CME Accreditation Page - p. 9 8. Preface: PET/CT: Defining Value to Patients and Health Systems - p. 10 9. Role of 2-Fluoro-2-Deoxyglucose PET/Computed Tomography in Carcinoma of Unknown Primary - p. 11 10. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers - p. 16 11. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas - p. 25 12. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer - p. 35 13. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer - p. 46 14. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas - p. 56 15. Fludeoxyglucose F 18 PET–Computed Tomography - p. 69 16. PET/Computed Tomography in Neuroendocrine Tumor - p. 78 17. 18F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors - p. 81 18. 18-Fluoro-deoxyglucose–PET/Computed Tomography in Infection and Aseptic Inflammatory Disorders - p. 86 19. Cardiac PET/Computed Tomography Applications and Cardiovascular Outcome - p. 90
No hay muestra disponible
No hay ficha técnica disponible
This two-part issue, edited by Dr. Rathan Subramaniam, reviews current clinical information in "PET/CT and Patient Outcomes." In Part II of this issue, articles will include: Hepatobiliary and Pancreatic Cancer; Endometrial, Cervical & Ovarian Cancer; Renal, Bladder and Testicular Cancer; Musculoskeletal and Soft Tissue Tumors; Myocardial Perfusion / Viability; Unknown Primary Cancer; Gastric Cancer; Brain Tumors; Neuroendocrine Tumors, and more!
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Copyright - p. 4 5. Contributors - p. 5 6. Forthcoming Issues - p. 8 7. CME Accreditation Page - p. 9 8. Preface: PET/CT: Defining Value to Patients and Health Systems - p. 10 9. Role of 2-Fluoro-2-Deoxyglucose PET/Computed Tomography in Carcinoma of Unknown Primary - p. 11 10. PET/Computed Tomography in the Diagnosis and Staging of Gastric Cancers - p. 16 11. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas - p. 25 12. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer - p. 35 13. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer - p. 46 14. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas - p. 56 15. Fludeoxyglucose F 18 PET–Computed Tomography - p. 69 16. PET/Computed Tomography in Neuroendocrine Tumor - p. 78 17. 18F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors - p. 81 18. 18-Fluoro-deoxyglucose–PET/Computed Tomography in Infection and Aseptic Inflammatory Disorders - p. 86 19. Cardiac PET/Computed Tomography Applications and Cardiovascular Outcome - p. 90
No hay muestra disponible
No hay ficha técnica disponible
